Indivior Pharmaceuticals (INDV) Return on Capital Employed (2025 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Return on Capital Employed of 79.29% for Q1 2026, up 7077.0% year-over-year from 1.1% in Q1 2025, and up 19.38% quarter-over-quarter from 66.41% in Q4 2025.
Indivior Pharmaceuticals (INDV) Return on Capital Employed (2025 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 79.29% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 7077.0% year-over-year to 79.29%; the TTM figure through Mar 2026 stood at 79.29% (up 7077.0% YoY), while the FY2025 annual figure was 76.05%, up 6985.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 79.29%, up from 66.41% in the prior quarter.
- The five-year high for Return on Capital Employed was 79.29% in Q1 2026, with the low at 8.52% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.56 Bn | 4.34 Bn | 294.00 Mn | 121.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 121.33% |
| Mar 31, 2026 | 79.29% |
| Dec 31, 2025 | 66.41% |
| Sep 30, 2025 | 48.40% |
| Jun 30, 2025 | 61.26% |
| Mar 31, 2025 | 8.52% |